MX2016013564A - Inhibidores heterociclicos de cinasas. - Google Patents
Inhibidores heterociclicos de cinasas.Info
- Publication number
- MX2016013564A MX2016013564A MX2016013564A MX2016013564A MX2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- heterocyclic kinase
- heterocyclic
- compounds
- stereoisomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención proporciona compuestos de la fórmula (I): (ver Fórmula) sales farmacéuticamente aceptables, profármacos, metabolitos biológicamente activos, estereoisómeros y sus isómeros, donde las variables se definen en el presente documento. Los compuestos de la invención son útiles para tratar dolencias inmunológicas y oncológicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/075560 WO2015157955A1 (en) | 2014-04-17 | 2014-04-17 | Heterocyclic btk inhibit ors |
PCT/CN2015/076766 WO2015158283A1 (en) | 2014-04-17 | 2015-04-16 | Heterocyclic kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016013564A true MX2016013564A (es) | 2017-05-09 |
Family
ID=54323386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016013564A MX2016013564A (es) | 2014-04-17 | 2015-04-16 | Inhibidores heterociclicos de cinasas. |
Country Status (9)
Country | Link |
---|---|
US (2) | US10280184B2 (es) |
EP (1) | EP3131900A4 (es) |
JP (1) | JP2017511365A (es) |
CN (1) | CN106459045A (es) |
AU (1) | AU2015246482A1 (es) |
BR (1) | BR112016024057A2 (es) |
CA (1) | CA2946036A1 (es) |
MX (1) | MX2016013564A (es) |
WO (2) | WO2015157955A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9932340B2 (en) * | 2014-12-18 | 2018-04-03 | Abbvie Inc. | Substituted indoles |
KR20180003614A (ko) * | 2015-05-12 | 2018-01-09 | 카리라 파마슈티컬스, 아이앤씨. | 바이사이클릭 화합물 |
CA3005723A1 (en) * | 2015-11-20 | 2017-05-26 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
US11352339B2 (en) | 2016-03-24 | 2022-06-07 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as DUB inhibitors |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
CN110337295B (zh) | 2016-11-28 | 2023-06-09 | 普拉克西斯精密药物股份有限公司 | 化合物以及它们的使用方法 |
US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
AU2018237123B2 (en) | 2017-03-22 | 2022-08-04 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
CN117903140A (zh) | 2018-02-27 | 2024-04-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
SG11202011879RA (en) | 2018-05-30 | 2020-12-30 | Praxis Prec Medicines Inc | Ion channel modulators |
SG11202013216RA (en) | 2018-07-05 | 2021-01-28 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
CN114555595B (zh) * | 2019-08-30 | 2023-12-26 | Tsd生命科学有限公司 | 咪唑并吡啶衍生物及将其作为有效成分的药学组合物 |
US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
EP3915990A1 (en) | 2020-05-26 | 2021-12-01 | Centre National de la Recherche Scientifique | 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer |
US20230203042A1 (en) * | 2020-06-01 | 2023-06-29 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as spleen tyrosine kinase inhibitors |
WO2021249417A1 (zh) * | 2020-06-09 | 2021-12-16 | 赛诺哈勃药业(成都)有限公司 | 杂环化合物及其衍生物 |
GB202014114D0 (en) * | 2020-09-08 | 2020-10-21 | Synairgen Res Ltd | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
EP4244223A1 (en) * | 2020-11-13 | 2023-09-20 | Biogen MA Inc. | Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors |
WO2023220049A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040102455A1 (en) * | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
DE60210755T2 (de) * | 2001-03-09 | 2006-11-16 | Pfizer Products Inc., Groton | Triazolopyridine als entzündungshemmende mittel |
US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
DE102004030782A1 (de) * | 2004-06-25 | 2006-01-19 | Fev Motorentechnik Gmbh | Fahrzeug-Steuergerät mit einem neuronalen Netz |
DE602005023333D1 (de) * | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
WO2007032936A2 (en) | 2005-09-09 | 2007-03-22 | Schering Corporation | Azafused cyclin dependent kinase inhibitors |
DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
PE20091074A1 (es) * | 2007-12-13 | 2009-07-26 | Bayer Healthcare Ag | Triazolotriazinas y triazolopirazinas y su uso |
CA2708361C (en) * | 2007-12-14 | 2016-06-07 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
WO2010006947A1 (en) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
AU2009325133B2 (en) | 2008-12-08 | 2016-02-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
EP2343294A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
CN103168039B (zh) | 2010-03-11 | 2016-08-03 | 吉利德康涅狄格公司 | 咪唑并吡啶类syk抑制剂 |
TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
US20140187548A1 (en) | 2010-12-17 | 2014-07-03 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
JP5951750B2 (ja) | 2011-04-06 | 2016-07-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾピリジン類およびその中間体 |
WO2012163724A1 (en) * | 2011-05-31 | 2012-12-06 | F. Hoffmann-La Roche Ag | Triazolopyridine compounds |
RU2662443C2 (ru) * | 2011-11-01 | 2018-07-26 | Ф. Хоффманн-Ля Рош Аг | Имидазопиридазины |
KR20140096100A (ko) * | 2011-11-03 | 2014-08-04 | 에프. 호프만-라 로슈 아게 | 이환 피페라진 화합물 |
CN103998447A (zh) * | 2011-12-09 | 2014-08-20 | 弗·哈夫曼-拉罗切有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
-
2014
- 2014-04-17 WO PCT/CN2014/075560 patent/WO2015157955A1/en active Application Filing
-
2015
- 2015-04-16 US US15/304,131 patent/US10280184B2/en active Active
- 2015-04-16 CN CN201580031633.1A patent/CN106459045A/zh active Pending
- 2015-04-16 WO PCT/CN2015/076766 patent/WO2015158283A1/en active Application Filing
- 2015-04-16 CA CA2946036A patent/CA2946036A1/en not_active Abandoned
- 2015-04-16 EP EP15780191.1A patent/EP3131900A4/en not_active Withdrawn
- 2015-04-16 JP JP2016562835A patent/JP2017511365A/ja active Pending
- 2015-04-16 AU AU2015246482A patent/AU2015246482A1/en not_active Abandoned
- 2015-04-16 BR BR112016024057A patent/BR112016024057A2/pt not_active Application Discontinuation
- 2015-04-16 MX MX2016013564A patent/MX2016013564A/es unknown
-
2018
- 2018-12-21 US US16/230,408 patent/US20190135836A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190135836A1 (en) | 2019-05-09 |
AU2015246482A1 (en) | 2016-10-27 |
EP3131900A4 (en) | 2017-11-15 |
US20170114077A1 (en) | 2017-04-27 |
US10280184B2 (en) | 2019-05-07 |
WO2015157955A1 (en) | 2015-10-22 |
BR112016024057A2 (pt) | 2017-08-15 |
CN106459045A (zh) | 2017-02-22 |
JP2017511365A (ja) | 2017-04-20 |
EP3131900A1 (en) | 2017-02-22 |
WO2015158283A1 (en) | 2015-10-22 |
CA2946036A1 (en) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016013564A (es) | Inhibidores heterociclicos de cinasas. | |
NZ754039A (en) | Primary carboxamides as btk inhibitors | |
PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
PH12018500342A1 (en) | Heterocyclic amides as kinase inhibitors | |
EP3752491A4 (en) | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
PH12017501523A1 (en) | Selective bace1 inhibitors | |
TW201613872A (en) | IRAK4 inhibiting agents | |
PH12017502237A1 (en) | Nuclear receptor modulators | |
PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
MA39749A (fr) | Dérivés de pipéridine-dione | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
NZ716392A (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
MX2017007607A (es) | Inhibidores de necrosis celular y metodos relacionados. | |
MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
EP3952865A4 (en) | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS FOR THERAPEUTIC USES | |
TW201612165A (en) | Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
EA201791596A1 (ru) | Пиразоловые соединения |